UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2015
Immune Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Florida | 000-54933 | 59-3226705 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| or incorporation) | File Number) | Identification Number) |
| 37 North Orange Avenue, Suite 607, Orlando, Florida | 32801 |
| (Address of principal executive offices) | (Zip Code) |
(888) 613 - 8802
(Registrant’s telephone number, including area code)
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| (1) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Compensatory Arrangements of Certain Officers
Immune Therapeutics, Inc. (the “Company”) is filing this Form 8-K/A to correct an error contained in its Current Report on Form 8-K which was filed with the Securities and Exchange Commission on January 14, 2015 (the “Current Report”). Specifically, the Current Report incorrectly reports that Seth Elliott will receive a monthly salary of $20,000 for the first six months and a monthly salary of $25,000 for the subsequent six months provided the Agreement (as defined in the Current Report) continues beyond the first six-month period. The correct statement is that The Sevin Group LLC will receive a monthly payment of $20,000 for the first six months and a monthly payment of $25,000 for the subsequent six months provided the Agreement continues beyond the first six-month period. No other items or disclosures in the Current Report are being amended.
| (2) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Immune Therapeutics, Inc. | ||
| By: /s/ Noreen Griffin | ||
| Noreen Griffin, Chief Executive Officer |
Date: January 22, 2015